Inhalt

Leistungsindikatoren

Die Leistungsindikatoren sind Werte, die aus den Daten hergeleitet werden, die dem Screeningprogramm selbst zur Verfügung stehen oder von diesem generiert werden, und eine laufende Beurteilung der Effektivität und der Qualität des Programmes zulassen. Diese Indikatoren umfassen technische, medizinische und administrative Parameter, deren Vergleich mit den Referenzwerten es ermöglicht, Aussagen über das Programm zu treffen, auch wenn die endgültigen Ziele noch nicht evaluierbar sind. Die laufende Evaluation der Leistungsindikatoren ermöglicht außerdem den Vergleich mit anderen regionalen und internationalen Mammographie-Screeningprogrammen.                                       

European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis – Leistungsindikatoren

 

Performance indicator	Acceptable level	Desirable level
1. Target optical density	1.4 - 1.9 OD	1.4 - 1.9 OD
2. Spatial resolution	> 12 lp/mm	> 15 lp/mm
3. Glandular dose – PMMA thickness at 4.5 cm	< 2.5 mGy	< 2.0 mGy
4. Threshold contrast visibility	< 1.5%	< 1.5%
5. Proportion of women invited that attend for screening	> 70%	> 75%
6. Proportion of eligible women reinvited within the specified screening interval	> 95%	100%
7. Proportion of eligible women reinvited within the specified screening interval + 6 month	> 98%	100%
8. Proportion of women with a radiographicallyacceptable screening examination	97%	> 97%
9. Proportion of women informed of procedure and time scale of receiving results	100%	100%
10. Proportion of women undergoing a technical repeat screening examination	< 3%	< 1%
11. Proportion of women undergoing additional imaging at the time of the screening examination in order to further clarify the mammographic appearances	< 5%	< 1%
12. Proportion of women recalled for further assessment     • initial screening examinations     • subsequent screening examinations	< 7% < 5%	< 5% < 3%
13. Proportion of screened women subjected to early recall following diagnostic assessment	< 1%	0%
14. Breast cancer detection rate, expressed as a multiple of the underlying, expected, breast cancer incidence rate in the absence of screening (IR)     • initial screening examinations     • subsequent-regular screening examinations	3 x IR 1.5 x IR	> 3 x IR0o0 > 1.5 x IR
15. Interval cancer rate as a proportion of the underlying, expected, breast cancer incidence rate in the absence of screening     • within the first year (0-11 months)     • within the second year (12-23 months)	30%0o 50%	< 30% < 50%
16. Proportion of screen-detected cancers that are invasive	90%	80-90%
17. Proportion of screen-detected cancers that are stage II+0     • initial screening examinations     • subsequent-regular screening examinations	NA0 25%	< 30% < 25%
18. Proportion of invasive screen-detected cancers0that are node-negative     • initial screening examinations     • subsequent-regular screening examinations	NA 75%	> 70% > 75%
19. Proportion of invasive screen-detected cancers that are £ 10 mm in size     • initial screening examinations     • subsequent-regular screening examinations	NA ³ 25%	³ 25% ³ 30%
20. Proportion of invasive screen-detected cancers0that are < 15 mm in size	50%	> 50%
21. Proportion of invasive screen-detected cancers < 10 mm in size for which there was no frozen section	95%	> 95%
22. Absolute sensitivity of FNAC	> 60%	> 70%
23. Complete sensitivity of FNAC	> 80%	> 90%
24. Specificity of FNAC	> 55%	> 65%
25. Absolute sensitivity of core biopsy	> 70%	> 80%
26. Complete sensitivity of core biopsy	> 80%	> 90%
27. Specificity of core biopsy	> 75%	> 85%
28. Proportion of localised impalpable lesions successfully excised at the first operation	> 90%	> 95%

Diese Seite  drucken  weiterempfehlen  bewerten